| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Multiple | D000015 | 13 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Insufficiency | D000309 | 3 associated lipids |
| Akinetic Mutism | D000405 | 1 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Alopecia Areata | D000506 | 6 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yanada M et al. | Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. | 2004 | Bone Marrow Transplant. | pmid:15220958 |
| Okano A et al. | Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation. | 2001 | Bone Marrow Transplant. | pmid:11704796 |
| Takahata M et al. | Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. | 2001 | Bone Marrow Transplant. | pmid:11704797 |
| Espino G et al. | Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. | 2001 | Bone Marrow Transplant. | pmid:11803349 |
| Watanabe N et al. | Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. | 2010 | Bone Marrow Transplant. | pmid:19915626 |
| Uberti JP et al. | Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. | 1997 | Bone Marrow Transplant. | pmid:9208118 |
| Ohashi Y et al. | Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. | 1997 | Bone Marrow Transplant. | pmid:9085743 |
| Mehta P et al. | Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. | 1999 | Bone Marrow Transplant. | pmid:10627642 |
| Messina C et al. | Prevention and treatment of acute GvHD. | 2008 | Bone Marrow Transplant. | pmid:18545247 |
| Hiraoka A et al. | Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. | 2001 | Bone Marrow Transplant. | pmid:11509936 |
| Yu C et al. | Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. | 1997 | Bone Marrow Transplant. | pmid:9244417 |
| Fujino M et al. | Intestinal thrombotic microangiopathy induced by FK506 in rats. | 2007 | Bone Marrow Transplant. | pmid:17277791 |
| Mori T et al. | Drug interaction between voriconazole and tacrolimus in allogeneic hematopoietic SCT recipients. | 2011 | Bone Marrow Transplant. | pmid:20453893 |
| Kanamaru A et al. | FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. | 1995 | Bone Marrow Transplant. | pmid:7581086 |
| Riley L et al. | Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. | 2000 | Bone Marrow Transplant. | pmid:10808214 |
| Ochiai N et al. | Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia. | 2002 | Bone Marrow Transplant. | pmid:12439703 |
| Yumura-Yagi K et al. | Unrelated donor bone marrow transplantation for 100 pediatric patients: a single institute's experience. | 2005 | Bone Marrow Transplant. | pmid:15968285 |
| Gondo H et al. | Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. | 2000 | Bone Marrow Transplant. | pmid:11149744 |
| Suehiro A et al. | Enhancement by cyclosporine A and tacrolimus of serotonin-induced formation of small platelet aggregation. | 2002 | Bone Marrow Transplant. | pmid:11850703 |
| Nelson R et al. | Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. | 2015 | Bone Marrow Transplant. | pmid:26301969 |
| Han CW et al. | Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. | 1995 | Bone Marrow Transplant. | pmid:7545487 |
| Terakura S et al. | Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. | 2017 | Bone Marrow Transplant. | pmid:27941766 |
| Zohren F et al. | Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. | 2011 | Bone Marrow Transplant. | pmid:20661230 |
| Esquirol A et al. | Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. | 2017 | Bone Marrow Transplant. | pmid:28604667 |
| Kanda J et al. | Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. | 2013 | Bone Marrow Transplant. | pmid:23334274 |
| Cooper MH et al. | Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. | 1994 | Bone Marrow Transplant. | pmid:7527689 |
| Boughton O et al. | A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. | 2013 | Br J Clin Pharmacol | pmid:23305195 |
| Antignac M et al. | Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. | 2007 | Br J Clin Pharmacol | pmid:17425625 |
| Nishimoto M et al. | Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. | 2017 | Br J Clin Pharmacol | pmid:28407449 |
| Böttiger Y et al. | Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. | 1999 | Br J Clin Pharmacol | pmid:10510159 |
| Cusinato DA et al. | Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. | 2014 | Br J Clin Pharmacol | pmid:24528196 |
| Mai I et al. | MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. | 2004 | Br J Clin Pharmacol | pmid:15521904 |
| Woillard JB et al. | Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. | 2010 | Br J Clin Pharmacol | pmid:20565459 |
| Tang JT et al. | The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. | 2017 | Br J Clin Pharmacol | pmid:27753146 |
| Hawwa AF et al. | Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. | 2009 | Br J Clin Pharmacol | pmid:19740399 |
| Zahir H et al. | Factors affecting variability in distribution of tacrolimus in liver transplant recipients. | 2004 | Br J Clin Pharmacol | pmid:14998426 |
| Atcheson BA et al. | Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. | 2005 | Br J Clin Pharmacol | pmid:15752372 |
| Jalil MH et al. | Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. | 2014 | Br J Clin Pharmacol | pmid:23738951 |
| Johnston A and Holt DW | Therapeutic drug monitoring of immunosuppressant drugs. | 1999 | Br J Clin Pharmacol | pmid:10233195 |
| Billaud EM et al. | Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. | 1998 | Br J Clin Pharmacol | pmid:9764970 |
| Horigome A et al. | Lymphocyte-sensitivity to glucocorticoid correlates with the sensitivity to cyclosporin A and tacrolimus in chronic renal failure patients. | 1999 | Br J Clin Pharmacol | pmid:10583028 |
| Øzbay LA et al. | Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. | 2012 | Br J Clin Pharmacol | pmid:21988494 |
| Størset E et al. | Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. | 2017 | Br J Clin Pharmacol | pmid:28374426 |
| Jacobo-Cabral CO et al. | Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. | 2015 | Br J Clin Pharmacol | pmid:25846845 |
| Størset E et al. | Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. | 2014 | Br J Clin Pharmacol | pmid:25279405 |
| Suzuki Y et al. | Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. | 2008 | Br J Clin Pharmacol | pmid:18341670 |
| Pham VV et al. | Graft rejection: pharmacogenetic analysis or drug anamnesis? | 2008 | Br J Clin Pharmacol | pmid:18341681 |
| Gonschior AK et al. | Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). | 1994 | Br J Clin Pharmacol | pmid:7534100 |
| Zhao CY et al. | External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. | 2016 | Br J Clin Pharmacol | pmid:26574188 |
| Barraclough KA et al. | Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. | 2011 | Br J Clin Pharmacol | pmid:21219401 |
| Cremers S et al. | Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. | 2005 | Br J Clin Pharmacol | pmid:16120063 |
| Barau C et al. | Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. | 2012 | Br J Clin Pharmacol | pmid:22329639 |
| Choi JH et al. | Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. | 2007 | Br J Clin Pharmacol | pmid:17391324 |
| Musuamba FT et al. | Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. | 2013 | Br J Clin Pharmacol | pmid:23072565 |
| Vanhove T et al. | Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. | 2016 | Br J Clin Pharmacol | pmid:27501475 |
| Woillard JB et al. | Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. | 2011 | Br J Clin Pharmacol | pmid:21284698 |
| Staatz CE et al. | Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose. | 2015 | Br J Clin Pharmacol | pmid:26235203 |
| Vanhove T et al. | Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'. | 2015 | Br J Clin Pharmacol | pmid:26235051 |
| Vanhove T et al. | Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. | 2017 | Br J Clin Pharmacol | pmid:28168728 |
| Størset E et al. | The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28146606 |
| Mück W et al. | Tacrolimus/cerivastatin interaction study in liver transplant recipients. | 2001 | Br J Clin Pharmacol | pmid:11488782 |
| Kassir N et al. | Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. | 2014 | Br J Clin Pharmacol | pmid:24977292 |
| Passey C et al. | Dosing equation for tacrolimus using genetic variants and clinical factors. | 2011 | Br J Clin Pharmacol | pmid:21671989 |
| Zheng S et al. | Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. | 2013 | Br J Clin Pharmacol | pmid:23528073 |
| Satoh S et al. | Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. | 2008 | Br J Clin Pharmacol | pmid:18429967 |
| de Jonge H et al. | Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. | 2015 | Br J Clin Pharmacol | pmid:26114223 |
| Xin HW et al. | Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. | 2007 | Br J Clin Pharmacol | pmid:17506780 |
| Mathew BS et al. | A limited sampling strategy for tacrolimus in renal transplant patients. | 2008 | Br J Clin Pharmacol | pmid:18662286 |
| Christians U et al. | Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. | 1996 | Br J Clin Pharmacol | pmid:8866917 |
| Sam WJ et al. | Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. | 2000 | Br J Clin Pharmacol | pmid:11136292 |
| Calvo PL et al. | Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. | 2017 | Br J Clin Pharmacol | pmid:28044353 |
| Stifft F et al. | Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. | 2014 | Br J Clin Pharmacol | pmid:24809233 |
| Størset E et al. | Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. | 2017 | Br J Clin Pharmacol | pmid:28008657 |
| Renders L et al. | Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. | 2003 | Br J Clin Pharmacol | pmid:12895195 |
| Knops N et al. | Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. | 2017 | Br J Clin Pharmacol | pmid:27966227 |
| Elens L et al. | The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. | 2013 | Br J Clin Pharmacol | pmid:23163400 |
| Bremer S et al. | NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. | 2017 | Br J Clin Pharmacol | pmid:28686294 |
| Elens L et al. | Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. | 2014 | Br J Clin Pharmacol | pmid:24118098 |
| Hesselink DA et al. | Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. | 2003 | Br J Clin Pharmacol | pmid:12919182 |
| Vanhove T et al. | Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. | 2017 | Br J Clin Pharmacol | pmid:28603840 |
| James DG | Which immunomodulator? | 1991 | Br J Clin Pract | pmid:1718384 |
| Bowman H and Lennard TW | Immunosuppressive drugs. | 1992 Nov 4-17 | Br J Hosp Med | pmid:1282440 |
| Shahid S et al. | Chronic hepatitis in the transplant patient. | 2017 | Br J Hosp Med (Lond) | pmid:28692371 |
| Murphy CC et al. | Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. | 2007 | Br J Ophthalmol | pmid:16973657 |
| Oh-i K et al. | Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. | 2007 | Br J Ophthalmol | pmid:16987901 |
| Tam PM et al. | Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis--case series. | 2010 | Br J Ophthalmol | pmid:20558422 |
| Young AL et al. | Allo-limbal transplantation in patients with limbal stem cell deficiency. | 1999 | Br J Ophthalmol | pmid:10574823 |
| Rao SK et al. | Limbal allografting using FK-506. | 1999 | Br J Ophthalmol | pmid:10574824 |
| Oh-i K et al. | Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). | 2007 | Br J Ophthalmol | pmid:17940132 |
| Fukushima A et al. | Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. | 2014 | Br J Ophthalmol | pmid:24695688 |
| Joseph A et al. | Tacrolimus immunosuppression in high-risk corneal grafts. | 2007 | Br J Ophthalmol | pmid:16956911 |
| Hogan A et al. | Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. | 2005 | Br J Ophthalmol | pmid:16113360 |
| Lake DB and Poole TR | Tacrolimus. | 2003 | Br J Ophthalmol | pmid:12488279 |
| Magalhaes OA et al. | Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. | 2013 | Br J Ophthalmol | pmid:24008822 |
| Shoughy SS and Tabbara KF | Topical tacrolimus solution in autoimmune polyglandular syndrome-1-associated keratitis. | 2017 | Br J Ophthalmol | pmid:28137823 |
| Leder HA et al. | Disappearance of classic birdshot spots after immunosuppression with tacrolimus and mycophenolate mofetil. | 2008 | Br J Ophthalmol | pmid:18227210 |
| Aoki S et al. | Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. | 2005 | Br J Ophthalmol | pmid:15665364 |
| Ortega KL et al. | Oral ulcers after a transplant. | 2010 | Br J Oral Maxillofac Surg | pmid:19231045 |
| Cetinkale O et al. | The use of FK506 and skin allografting for the treatment of severe burns in an animal model. | 1993 | Br J Plast Surg | pmid:7690295 |
| Ahn KJ et al. | Diffusion-weighted MRI and ADC mapping in FK506 neurotoxicity. | 2003 | Br J Radiol | pmid:14711782 |